Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
$2.78
-3.5%
$2.53
$1.60
$15.65
$75.26M1.65409,643 shs83,094 shs
Assertio Holdings, Inc. stock logo
ASRT
Assertio
$0.67
+0.4%
$0.66
$0.51
$1.70
$64.46M0.29519,184 shs196,154 shs
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$1.26
-2.3%
$1.60
$1.09
$7.67
$15.50M0.5348,193 shs15,904 shs
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$0.41
-31.9%
$0.81
$0.32
$1.65
$31.78M2.05390,967 shs3.61 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
0.00%+6.72%+23.01%+23.83%-82.93%
Assertio Holdings, Inc. stock logo
ASRT
Assertio
0.00%-2.60%+2.11%+10.26%-59.46%
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
0.00%-10.00%-7.35%-37.62%-79.97%
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
0.00%-53.67%-48.10%-52.33%-66.12%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
1.9655 of 5 stars
3.33.00.00.00.00.81.3
Assertio Holdings, Inc. stock logo
ASRT
Assertio
1.8651 of 5 stars
3.50.00.00.02.10.81.3
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
3.7095 of 5 stars
3.53.00.04.30.61.70.0
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
2.1096 of 5 stars
4.13.00.00.01.50.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
2.57
Moderate Buy$8.50205.76% Upside
Assertio Holdings, Inc. stock logo
ASRT
Assertio
3.00
Buy$2.75308.62% Upside
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
3.00
Buy$4.00217.46% Upside
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
2.17
Hold$4.20924.39% Upside

Current Analyst Ratings Breakdown

Latest CASI, ANRO, CLSD, and ASRT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/18/2025
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$5.00
7/18/2025
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
7/18/2025
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$2.00
7/17/2025
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/17/2025
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeModerate Buy ➝ Hold$3.00
6/26/2025
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/23/2025
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.00 ➝ $5.00
5/19/2025
Assertio Holdings, Inc. stock logo
ASRT
Assertio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.50 ➝ $3.50
5/19/2025
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
5/16/2025
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$5.00 ➝ $5.00
5/15/2025
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/AN/AN/AN/A$5.62 per shareN/A
Assertio Holdings, Inc. stock logo
ASRT
Assertio
$124.96M0.52$0.05 per share13.71$1.27 per share0.53
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$28.54M0.54N/AN/A$0.12 per share10.50
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$1.66M19.19N/AN/A($0.51) per share-0.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-$61.43M-$2.34N/AN/AN/AN/A-39.35%-33.86%8/12/2025 (Estimated)
Assertio Holdings, Inc. stock logo
ASRT
Assertio
-$21.58M-$0.32N/A22.43N/A-25.72%-24.87%-10.87%8/6/2025 (Estimated)
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
-$39.26M-$2.55N/AN/A-129.05%-972.55%-77.33%8/15/2025 (Estimated)
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
-$34.35M-$0.41N/AN/AN/A-818.57%N/A-114.23%8/11/2025 (Estimated)

Latest CASI, ANRO, CLSD, and ASRT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/15/2025N/A
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
-$0.47N/AN/AN/A$6.28 millionN/A
8/12/2025Q2 2025
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-$0.57N/AN/AN/AN/AN/A
8/11/2025Q2 2025
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
-$0.12N/AN/AN/A$0.50 millionN/A
8/6/2025Q2 2025
Assertio Holdings, Inc. stock logo
ASRT
Assertio
-$0.06N/AN/AN/A$27.86 millionN/A
5/16/2025Q1 2025
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
-$0.61-$0.69-$0.08-$0.69$7.39 million$6.24 million
5/14/2025Q1 2025
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
-$0.12-$0.11+$0.01-$0.11$0.20 million$2.33 million
5/13/2025Q1 2025
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-$0.59-$0.53+$0.06-$0.56N/AN/A
5/12/2025Q1 2025
Assertio Holdings, Inc. stock logo
ASRT
Assertio
-$0.06-$0.14-$0.08-$0.14$27.52 million$26.49 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/AN/AN/AN/AN/A
Assertio Holdings, Inc. stock logo
ASRT
Assertio
N/AN/AN/AN/AN/A
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
N/AN/AN/AN/AN/A
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
0.15
22.53
22.53
Assertio Holdings, Inc. stock logo
ASRT
Assertio
0.36
1.66
1.35
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
N/A
0.81
0.68
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
N/A
3.19
3.19

Institutional Ownership

CompanyInstitutional Ownership
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/A
Assertio Holdings, Inc. stock logo
ASRT
Assertio
48.96%
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
22.23%
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
18.75%

Insider Ownership

CompanyInsider Ownership
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
11.13%
Assertio Holdings, Inc. stock logo
ASRT
Assertio
4.00%
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
21.24%
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
6.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/A27.07 million24.06 millionN/A
Assertio Holdings, Inc. stock logo
ASRT
Assertio
2095.78 million91.95 millionOptionable
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
18012.30 million9.69 millionOptionable
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
3077.71 million72.89 millionOptionable

Recent News About These Companies

Needham Downgrades Clearside Biomedical (CLSD)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alto Neuroscience stock logo

Alto Neuroscience NYSE:ANRO

$2.78 -0.10 (-3.47%)
Closing price 07/18/2025 03:59 PM Eastern
Extended Trading
$2.77 -0.01 (-0.36%)
As of 07/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Assertio stock logo

Assertio NASDAQ:ASRT

$0.67 +0.00 (+0.45%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$0.68 +0.00 (+0.59%)
As of 07/18/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

CASI Pharmaceuticals stock logo

CASI Pharmaceuticals NASDAQ:CASI

$1.26 -0.03 (-2.33%)
Closing price 07/18/2025 03:59 PM Eastern
Extended Trading
$1.27 +0.01 (+0.48%)
As of 07/18/2025 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Clearside Biomedical stock logo

Clearside Biomedical NASDAQ:CLSD

$0.41 -0.19 (-31.87%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$0.42 +0.01 (+1.95%)
As of 07/18/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.